1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market
Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market Drivers,
Challenges, Trends
4.
Voice of Customer
5. Global Formulation Development Outsourcing Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value
5.2.
Market Share & Forecast
5.2.1. By Service
(Preformulation, Formulation Development)
5.2.2. By Formulation (Oral, Injectable, Topical,
Others)
5.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others )
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle
East & Africa)
5.2.5. By Company (2022)
5.3.
Market Map
5.3.1 By Service
5.3.2 By Formulation
5.3.3 By Therapeutic
Area
5.3.4 By Region
6.
North America Formulation Development Outsourcing
Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Service (Preformulation, Formulation Development)
6.2.2. By Formulation (Oral, Injectable, Topical, Others)
6.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
6.2.4. By Country
6.3.
North America: Country Analysis
6.3.1. United States
Formulation Development Outsourcing Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Service
6.3.1.2.2.
By Formulation
6.3.1.2.3.
By Therapeutic Area
6.3.2. Canada Formulation
Development Outsourcing Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Service
6.3.2.2.2.
By Formulation
6.3.2.2.3.
By Therapeutic Area
6.3.3. Mexico Formulation
Development Outsourcing Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Service
6.3.3.2.2.
By Formulation
6.3.3.2.3.
By Therapeutic Area
7. Europe Formulation Development
Outsourcing Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Service (Preformulation, Formulation Development)
7.2.2. By Formulation (Oral, Injectable,
Topical, Others)
7.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology,
Hematology, Respiratory, Cardiovascular, Dermatology, Others)
7.2.4. By Country
7.3.
Europe: Country Analysis
7.3.1. France Formulation
Development Outsourcing Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Service
7.3.1.2.2.
By Formulation
7.3.1.2.3.
By Therapeutic Area
7.3.2. Germany Formulation
Development Outsourcing Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Service
7.3.2.2.2.
By Formulation
7.3.2.2.3.
By Therapeutic Area
7.3.3. United Kingdom
Formulation Development Outsourcing Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Service
7.3.3.2.2.
By Formulation
7.3.3.2.3.
By Therapeutic Area
7.3.4. Italy Formulation
Development Outsourcing Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Service
7.3.4.2.2.
By Formulation
7.3.4.2.3.
By Therapeutic Area
7.3.5. Spain Formulation
Development Outsourcing Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Service
7.3.5.2.2.
By Formulation
7.3.5.2.3.
By Therapeutic Area
8. Asia-Pacific
Formulation Development Outsourcing Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Service (Preformulation, Formulation Development)
8.2.2. By Formulation (Oral, Injectable,
Topical, Others)
8.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology,
Hematology, Respiratory, Cardiovascular, Dermatology, Others)
8.2.4.
By Country
8.3.
Asia-Pacific: Country Analysis
8.3.1. China Formulation
Development Outsourcing Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Service
8.3.1.2.2.
By Formulation
8.3.1.2.3.
By Therapeutic Area
8.3.2. India Formulation Development
Outsourcing Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Service
8.3.2.2.2.
By Formulation
8.3.2.2.3.
By Therapeutic Area
8.3.3. Japan Formulation
Development Outsourcing Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Service
8.3.3.2.2.
By Formulation
8.3.3.2.3.
By Therapeutic Area
8.3.4. South Korea
Formulation Development Outsourcing Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Service
8.3.4.2.2.
By Formulation
8.3.4.2.3.
By Therapeutic Area
8.3.5. Australia
Formulation Development Outsourcing Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Service
8.3.5.2.2.
By Formulation
8.3.5.2.3.
By Therapeutic Area
9. South America
Formulation Development Outsourcing Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Service (Preformulation, Formulation Development)
9.2.2. By Formulation (Oral, Injectable,
Topical, Others)
9.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology,
Hematology, Respiratory, Cardiovascular, Dermatology, Others)
9.2.4.
By Country
9.3.
South America: Country Analysis
9.3.1. Brazil Formulation
Development Outsourcing Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Service
9.3.1.2.2.
By Formulation
9.3.1.2.3.
By Therapeutic Area
9.3.2. Argentina
Formulation Development Outsourcing Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Service
9.3.2.2.2.
By Formulation
9.3.2.2.3.
By Therapeutic Area
9.3.3. Colombia Formulation
Development Outsourcing Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Service
9.3.3.2.2.
By Formulation
9.3.3.2.3.
By Therapeutic Area
10. Middle East and
Africa Formulation Development Outsourcing Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Service (Preformulation, Formulation Development)
10.2.2. By Formulation (Oral, Injectable,
Topical, Others)
10.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology,
Hematology, Respiratory, Cardiovascular, Dermatology, Others)
10.2.4.
By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa
Formulation Development Outsourcing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Service
10.3.1.2.2.
By Formulation
10.3.1.2.3.
By Therapeutic Area
10.3.2. Saudi Arabia
Formulation Development Outsourcing Market Outlook
10.3.2.1. Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Service
10.3.2.2.2.
By Formulation
10.3.2.2.3.
By Therapeutic Area
10.3.3. UAE Formulation
Development Outsourcing Market Outlook
10.3.3.1. Market Size &
Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Service
10.3.3.2.2.
By Formulation
10.3.3.2.3.
By Therapeutic Area
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Development
12.2.
Mergers & Acquisitions
12.3.
Product Launches
13. Global Formulation Development Outsourcing Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Products
15.
Competitive Landscape
15.1.
Business Overview
15.2.
Product Offerings
15.3.
Recent Developments
15.4.
Financials (As Reported)
15.5.
Key Personnel
15.6.
SWOT Analysis
15.6.1 Charles River Laboratories.
15.6.2 Aizant Drug Research Solutions Private Limited.
15.6.3 Catalent Inc.
15.6.4 Laboratory Corporation of America Holdings.
15.6.5 Syngene International Ltd.
15.6.6 Irisys LLC.
15.6.7 Intertek Group PLC.
15.6.8 Piramal Pharma Solutions.
15.6.9 Qiotient Sciences Ltd.
15.6.10
Patheon Inc.
15.6.11
Emergent BioSolutions Inc
15.6.12
Lonza Group AG
16. Strategic Recommendations